<DOC>
	<DOC>NCT00757419</DOC>
	<brief_summary>The aim is to establish the maximal tolerated dose of AZD3355 for the selection of doses in the up-coming studies. This will be done by comparing single and repeated doses of AZD3355 to placebo ("inactive substance"). Safety and tolerability variables will be closely monitored throughout the study.</brief_summary>
	<brief_title>AZD3355 Dose-escalation Study in Healthy Males</brief_title>
	<detailed_description />
	<mesh_term>Lesogaberan</mesh_term>
	<criteria>Subjects without concurrent diseases who do not require any medical treatments Provision of signed informed consent. History of somatic disease/condition, which may interfere with the objectives for the study, as judged by the investigator. Clinically significant illness or clinically relevant trauma within the 2 weeks prior to the administration of the investigational product, as judged by the investigator. History of clinically significant orthostatic reaction or syncope Clinically important abnormalities related to the heart function</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>healthy subjects</keyword>
</DOC>